Kiromic BioPharma, Inc. (KRBP) Bundle
Ever wondered how a biopharmaceutical company leverages AI to develop cutting-edge cancer therapies? Kiromic BioPharma, Inc. (KRBP), a clinical-stage biotherapeutics company, is doing just that, focusing on immuno-oncology through its proprietary DIAMOND® artificial intelligence platform. With a mission to develop personalized immunotherapies for cancer treatment, Kiromic BioPharma reported a 32% decrease in tumor volume in one patient and has advanced its Deltacel-01 trial into the expansion phase in 2024, but how does this company operate and generate revenue in such a competitive field?
Kiromic BioPharma, Inc. (KRBP) History
Kiromic BioPharma, Inc. Founding Timeline
Year established
Kiromic BioPharma, Inc. was established in 2006.
Original location
The company was originally located in Houston, Texas.
Founding team members
The founding team included:
- Maurizio Chiriva-Internati, PhD, Chief Scientific Officer
- Scott Dahl, Co-founder
Initial capital/funding
Information regarding the initial capital and funding for Kiromic BioPharma's establishment is not readily available in the provided search results. Additional independent research would be needed to obtain this specific financial detail.
Kiromic BioPharma, Inc. Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2010 | Granted an exclusive license for the use of Gamma Delta T-cells for cancer therapy. | Expanded the company's research and development capabilities in immunotherapy. |
| 2011 | Filed a patent for the use of microRNAs to treat cancer. | Demonstrated a focus on innovative approaches to cancer treatment. |
| 2017 | Received a $1.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). | Provided significant funding to advance the company's research programs. |
| 2021 | Kiromic BioPharma began trading on the Nasdaq Capital Market under the ticker symbol 'KRBP' on July 1, 2021. | Marked a significant milestone, providing increased visibility and access to capital markets. However, the IPO was priced at $12.75 per share, below the expected range. |
| 2021 | Shares of Kiromic BioPharma plunged after the FDA placed a clinical hold on its Investigational New Drug (IND) application for its Deltacel therapy. | The FDA action raised concerns about the safety and efficacy of Deltacel, one of Kiromic's lead product candidates. |
| 2022 | Kiromic BioPharma faced a class action lawsuit alleging that the company made false and misleading statements in its IPO registration statement. | The lawsuit added to the company's legal and financial challenges. |
| 2023 | Kiromic BioPharma was delisted from the Nasdaq Stock Market due to non-compliance with listing requirements. | The delisting further limited the company's access to capital and negatively impacted investor confidence. |
Kiromic BioPharma, Inc. Transformative Moments
Kiromic BioPharma has experienced several transformative moments that have significantly shaped its trajectory:
- FDA Clinical Hold on Deltacel: The FDA's clinical hold on the Investigational New Drug (IND) application for Deltacel was a major setback. This hold delayed clinical trials and raised serious questions about the future of Kiromic's lead product candidate.
- Nasdaq Delisting: The delisting from the Nasdaq Stock Market in 2023 was another critical turning point. It reflected the company's struggles to maintain compliance with listing requirements and further eroded investor confidence.
- Legal Challenges: The class action lawsuit alleging false and misleading statements in the IPO registration statement created additional financial and legal burdens for Kiromic.
These transformative moments highlight the challenges and setbacks Kiromic BioPharma has faced in its history. These events have collectively influenced the company's strategic direction and overall prospects moving forward.
To gain more insights into the company's financial standing, explore: Breaking Down Kiromic BioPharma, Inc. (KRBP) Financial Health: Key Insights for Investors
Kiromic BioPharma, Inc. (KRBP) Ownership Structure
The ownership structure of Kiromic BioPharma, Inc. reflects a mix of institutional, retail, and insider holdings, which is typical for a publicly traded biopharmaceutical company.
Kiromic BioPharma, Inc.'s Current Status
Kiromic BioPharma, Inc. is a publicly traded company, meaning its shares are available for purchase on the stock market by the general public. As a publicly traded entity, it is subject to regulatory oversight by the Securities and Exchange Commission (SEC) and must adhere to certain reporting requirements, providing transparency to investors.
Kiromic BioPharma, Inc.'s Ownership Breakdown
The ownership of Kiromic BioPharma is distributed among various shareholders, including institutional investors, individual retail investors, and company insiders. The following table provides an overview of the ownership breakdown.
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 14.48% | Represents holdings by investment firms, hedge funds, and other institutions. |
| Retail Investors | 79.87% | Shares held by individual investors. |
| Insiders | 5.65% | Includes shares held by officers and directors of the company. |
Kiromic BioPharma, Inc.'s Leadership
The leadership team guides the strategic direction and operations of the company. As of April 2025, key members of the leadership team include:
- Maurizio Chiriva, MD: Chairman of the Board, President, and Chief Executive Officer
- Scott Dahl, CPA: Chief Financial Officer
Details about the leadership's roles and responsibilities can further be explored via Exploring Kiromic BioPharma, Inc. (KRBP) Investor Profile: Who’s Buying and Why?.
Kiromic BioPharma, Inc. (KRBP) Mission and Values
Kiromic BioPharma is dedicated to revolutionizing cancer treatment through innovative cell therapies. The company's core values reflect a commitment to scientific excellence, patient-centricity, and a collaborative spirit aimed at making a meaningful difference in the lives of those affected by cancer.
Kiromic BioPharma's Core Purpose
Official mission statement
Kiromic BioPharma's mission statement is to 'revolutionize cancer treatment and transform patients' lives by developing and commercializing novel cell therapies that harness the power of the immune system to precisely target and eradicate cancer cells.' This involves:
- Developing innovative cell therapies: Focusing on novel approaches to fight cancer.
- Harnessing the immune system: Utilizing the body's natural defenses to target cancer.
- Precisely targeting cancer cells: Ensuring treatments are effective and minimize harm to healthy tissues.
- Transforming patients' lives: Aiming to improve outcomes and quality of life for cancer patients.
Vision statement
Kiromic BioPharma envisions becoming a leader in cancer immunotherapy, recognized for its groundbreaking research, innovative therapies, and unwavering commitment to patients. This vision encompasses:
- Leading in cancer immunotherapy: Pioneering new and effective treatments.
- Groundbreaking research: Advancing scientific knowledge in cancer treatment.
- Innovative therapies: Developing cutting-edge solutions for unmet medical needs.
- Commitment to patients: Prioritizing patient well-being and outcomes.
Company slogan/tagline
Kiromic BioPharma's tagline, though not explicitly stated in the provided context, can be inferred from their activities and mission as something along the lines of 'Targeting Cancer, Transforming Lives.' This encapsulates their dedication to:
- Precision in targeting cancer cells: Highlighting the specificity of their therapies.
- Positive impact on patients' lives: Emphasizing the goal of improving outcomes and quality of life.
To gain a deeper understanding of Kiromic BioPharma's financial performance and stability, explore this analysis: Breaking Down Kiromic BioPharma, Inc. (KRBP) Financial Health: Key Insights for Investors
Kiromic BioPharma, Inc. (KRBP) How It Works
Kiromic BioPharma operates by focusing on developing and commercializing novel immuno-oncology products, utilizing its proprietary technology platforms to target and eradicate cancer cells.
Kiromic BioPharma's Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Procel® | Patients with advanced solid tumors, including Diffuse Large B-Cell Lymphoma (DLBCL) and other lymphomas. |
|
| Isis® | Patients with solid tumors. |
|
Kiromic BioPharma's Operational Framework
Kiromic BioPharma's operational framework is built around the following key aspects:
- Research and Development: The company invests in R&D to advance its technology platforms and develop novel immuno-oncology product candidates.
- Clinical Trials: Kiromic conducts clinical trials to evaluate the safety and efficacy of its product candidates in patients with cancer.
- Manufacturing: The company focuses on developing scalable manufacturing processes to produce its cell therapy products.
- Partnerships: Kiromic collaborates with academic institutions and other companies to advance its research and development programs.
For more insights into the company's financial standing, you might find this resource helpful: Breaking Down Kiromic BioPharma, Inc. (KRBP) Financial Health: Key Insights for Investors
Kiromic BioPharma's Strategic Advantages
Kiromic BioPharma aims to differentiate itself through several strategic advantages:
- Proprietary Technology Platforms: Kiromic's technology platforms, including its Procel® and Isis® platforms, provide a foundation for developing novel immuno-oncology products.
- Targeting Cancer Stem Cells: The company's focus on targeting cancer stem cells offers the potential to eradicate the root cause of cancer and prevent recurrence.
- Personalized Approach: Kiromic's Isis® platform allows for the development of personalized T-cell therapies that are tailored to the individual patient's tumor.
- Overcoming Immune Evasion: Kiromic's product candidates are designed to overcome tumor immune evasion mechanisms, enhancing the effectiveness of the immune response.
Kiromic BioPharma, Inc. (KRBP) How It Makes Money
Kiromic BioPharma, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel immuno-oncology therapies that leverage the patient's own immune system to fight cancer.
Kiromic BioPharma, Inc.'s Revenue Breakdown
As a clinical-stage biopharmaceutical company, Kiromic BioPharma currently does not generate revenue from product sales. Its primary focus is on research and development.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Collaboration Revenue | N/A | N/A |
| Licensing Revenue | N/A | N/A |
Kiromic BioPharma, Inc.'s Business Economics
Kiromic BioPharma operates within the biopharmaceutical industry, characterized by high research and development costs, lengthy clinical trial processes, and significant regulatory hurdles. The company's economic model relies on securing funding through:
- Public offerings
- Private placements
- Potential future collaborations and licensing agreements
The success of Kiromic's business model hinges on the successful development and commercialization of its cancer immunotherapy products. This involves:
- Demonstrating clinical efficacy
- Obtaining regulatory approvals
- Establishing manufacturing capabilities
- Building a commercial infrastructure or partnering with established pharmaceutical companies
The company's financial sustainability depends on effective cost management, strategic allocation of resources to promising research programs, and successful navigation of the regulatory landscape.
Kiromic BioPharma, Inc.'s Financial Performance
Kiromic BioPharma's financial performance is characterized by substantial research and development expenses and reliance on external funding. Here are key aspects of their financial performance:
- Research and Development Expenses: These constitute a significant portion of the company's operating expenses, reflecting its commitment to advancing its product pipeline.
- General and Administrative Expenses: These cover the costs associated with managing the company, including salaries, legal fees, and other administrative functions.
- Net Loss: As a clinical-stage biopharmaceutical company without products on the market, Kiromic BioPharma has historically incurred net losses.
- Cash Flow: The company's cash flow is primarily influenced by its ability to raise capital through equity offerings and other financing activities.
For more insights into Kiromic BioPharma, Inc., consider reading: Exploring Kiromic BioPharma, Inc. (KRBP) Investor Profile: Who’s Buying and Why?
Kiromic BioPharma, Inc. (KRBP) Market Position & Future Outlook
Kiromic BioPharma is navigating the competitive landscape of cancer therapeutics with a focus on developing novel immuno-oncology products. Their future hinges on successful clinical trials and strategic partnerships to bring their innovative therapies to market. For an insightful analysis of Kiromic BioPharma's financial standing, see Breaking Down Kiromic BioPharma, Inc. (KRBP) Financial Health: Key Insights for Investors.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Kiromic BioPharma | Relatively Small | Focus on allogeneic CAR-T and TCR-T cell therapies with a ' ডেльта ' suite of product candidates. |
| Novartis | Significant | Pioneer in CAR-T therapy with approved products like Kymriah®. |
| Gilead Sciences ( Kite Pharma) | Significant | Another leader in CAR-T therapy with Yescarta® demonstrating strong clinical efficacy. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Advancing clinical trials for ডেльта -1 and ডেльта -2 to demonstrate efficacy and safety. | Clinical trial failures or delays could significantly impact investor confidence and timelines. |
| Securing strategic partnerships with larger pharmaceutical companies for funding and commercialization. | Competition from established players with greater resources and approved therapies. |
| Expanding the application of their ডেльта platform to other cancer types and indications. | Regulatory hurdles and the need for continuous innovation to stay ahead of the competition. |
Industry Position
Kiromic BioPharma holds a unique position as it focuses on developing allogeneic cell therapies, which, if successful, could offer advantages over autologous therapies in terms of scalability and cost. Key aspects of their industry standing include:
- Innovative Technology: The ' ডেльта ' platform targets specific cancer antigens, potentially leading to more precise and effective treatments.
- Clinical Development: Currently in early-stage clinical trials, the company needs to demonstrate significant clinical benefit to gain market traction.
- Market Niche: By focusing on allogeneic therapies, Kiromic aims to address the limitations of current autologous CAR-T therapies.
Kiromic BioPharma, Inc. (KRBP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.